Nothing new on German medtech companies' wish list
This article was originally published in Clinica
Executive Summary
As the new year takes off with reservations expressed about the strength of a European economic recovery, German medical technology companies have once again set out their stalls for the political establishment to view and digest. There is no room for heart-warming libations as dispensed by the picturesque Christmas markets in Munich, Stuttgart or Dresden, but a series of hard-hitting demands aimed at pressurising the government in Berlin into fulfilling its obligations as laid down in the coalition agreement of 2009. In this document, the Christian Democratic and Socialist Union Parties (CDU/CSU), together with the Liberals (FDP) aspired to improving the “potential and readiness” of the German medtech industry to innovate.
You may also be interested in...
MHRA’s Beneficial EU Relationship And Profitable Synergies With NICE: An Interview With Michael Rawlins
In December, Michael Rawlins was appointed head of the U.K.’s Medicines and Healthcare products Regulatory Agency. He recognizes the MHRA’s mutually beneficial relationship with European counterparts and is looking to safeguard synergies with other national regulatory bodies and NICE.
EMA Acts To Freeze GVK Drugs, Guard Against Shortages
The EMA has recommended suspension of some 700 drug formations linked with Indian clinical trials company GVK Biosciences, but assures national agencies that this won’t result in shortages or safety issues.
EMA Acts To Freeze Drugs Linked to GVK Bio, Guards Against Shortages
EMA has recommended suspension of some 700 drug formations linked with Indian clinical trials company GVK Biosciences, but assures national agencies that this won’t result in shortages or safety issues.